6336-68-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(PIPERIDINE-1-SULFONYL)-PHENYLAMINE is used as a research compound for the development of new drugs, leveraging its ability to act as a receptor antagonist or agonist. Its unique structure and functional groups enable it to target specific biological pathways and receptors, which is crucial for the treatment of various diseases and conditions.
Used in Targeting Specific Biological Pathways and Receptors:
In the field of medicinal chemistry, 4-(PIPERIDINE-1-SULFONYL)-PHENYLAMINE is used as a molecular probe to understand and modulate the activity of specific biological pathways and receptors. This application is vital for identifying new therapeutic targets and developing drugs with increased selectivity and efficacy.
Used in Investigation of Pharmacokinetic and Pharmacodynamic Properties:
4-(PIPERIDINE-1-SULFONYL)-PHENYLAMINE is employed in preclinical studies to investigate its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, as well as its pharmacodynamic properties, including its mechanism of action and effects on biological systems. This research is essential for assessing the compound's safety, efficacy, and potential for clinical use.

InChI:InChI=1/C11H16N2O2S/c12-10-4-6-11(7-5-10)16(14,15)13-8-2-1-3-9-13/h4-7H,1-3,8-9,12H2

Upstream product

• 5702-82-9 N-[4-(piperidin-1-sulfonyl)phenyl]acetamide 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 110-89-4 piperidine 
• 64268-93-5 1-((4-nitrophenyl)sulfonyl)piperidine 

Downstream Products

• 237385-71-6 [4-(piperidine-1-sulfonyl)-phenyl]-thiourea 
• 854476-87-2 1-(4-amino-3-thiocyanato-benzenesulfonyl)-piperidine 
• 116691-40-8 5-[4-(Piperidine-1-sulfonyl)-phenylazo]-quinolin-8-ol 
• 7356-55-0 1-(4-isothiocyanatobenzenesulfonyl)piperidine 
• 356100-11-3 [4-(piperidin-1-ylsulfonyl)phenylhydrazono]malonitrile 
• 848085-07-4 cyano-{[4-(piperidine-1-sulfonyl)-phenyl]-hydrazono}-acetic acid ethyl ester 
• 1026744-60-4 N-{6-Acetylamino-9-[4-(piperidine-1-sulfonyl)-phenylamino]-acridin-3-yl}-acetamide 
• 88327-95-1 [4-(Piperidine-1-sulfonyl)-phenylamino]-acetic acid 

Relevant academic research and scientific papers

Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation

In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens with a cell-based nuclear factor κB (NF-κB) reporter assay, we identified a sulfamoyl benzamidothiazole bearing compound 1 that demonstrated a sustained activation of NF-κB after a primary stimulus with a Toll-like receptor (TLR)-4 agonist, lipopolysaccharide (LPS). Here, we explore systematic structure–activity relationship (SAR) studies on compound 1 that indicated the sites on the scaffold that tolerated modification and yielded more potent compounds compared to 1. The selected analogs enhanced release of immunostimulatory cytokines in the human monocytic cell line THP-1 cells and murine primary dendritic cells. In murine vaccination studies, select compounds were used as co-adjuvants in combination with the Food and Drug Administration approved TLR-4 agonistic adjuvant, monophosphoryl lipid A (MPLA) that showed significant enhancement in antigen-specific antibody titers compared to MPLA alone. Additionally, our SAR studies led to identification of a photoaffinity probe which will aid the target identification and mechanism of action studies in the future.

Synthesis, characterization, and antiplasmodial efficacy of sulfonamide-appended [1,2,3]-triazoles

A series of benzenesulfonamide-appended [1,2,3]-triazole hybrids was synthesized by using [3 + 2] cycloaddition of primary, secondary, and tertiary sulfonamide azides with various phenoxymethylacetylenes under click reaction conditions. After structural c

VACCINE ADJUVANT

Compounds useful as an adjuvant, e.g., formulas (I)-(VI) and uses thereof, for example, with immunogenic moieties or other adjuvants, are provided.

Ammonium chloride-catalyzed four-component sonochemical synthesis of novel hexahydroquinolines bearing a sulfonamide moiety

Ammonium chloride as a very inexpensive and readily available reagent efficiently catalyzes one-pot four-component condensation of dimedone with aromatic aldehyde, malononitrile or ethyl cyanoacetate, and sulfonamide derivatives in ethanol at 70°C under ultrasonic irradiation to afford the corresponding 2-amino-4-aryl-1,4,5,6,7,8-hexahydroquinolines bearing a sulfonamide moiety in high yields. In comparison to conventional methods, high yields, easy work-up, and short reaction time are advantages of this sonochemical procedure. The effects of the catalyst, solvent, and temperature are assessed.

1,2-Benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors

A novel series of 1,2-benzisothiazol-3-one derivatives was synthesized and their biological activities were evaluated for inhibiting caspase-3 and -7 activities, in which some of them showed low nanomolar potency against caspase-3 in vitro and significant protection against apoptosis in a camptothecin-induced Jurkat T cells system. Among the tested compounds, compound 5i exhibited the most potent caspase-3 inhibitory activity (IC50 = 1.15 nM). The molecular docking predicted the interactions and binding modes of the synthesized inhibitor in the caspase-3 active site.

Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex

Measles virus (MV) is one of the most infectious pathogens known. In spite of the existence of a vaccine, approximately 350000 deaths/year result from MV or associated complications. Antimeasles compounds could conceivably diminish these statistics and pr

Synthesis and antimicrobial evaluation of guanylsulfonamides

A series of guanylsulfonamides, 2-amino-9-[2-substituted-4-(4-substituted piperidin-1-sulfonyl)phenyl]-1,9-dihydropurin-6-ones, was synthesized by adopting reductive aminoformylation of 2-amino-5-nitro-6-[4-(piperidin-1-sulfonyl)phenylamino]-3H-pyrimidin- 4-one and subsequent intramolecular ring condensation as key steps. All the guanylsulfonamides were assayed for their in vitro antibacterial activities against Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus aureus, and Streptococcus faecalis, and their antifungal activities against Aspergillus flavus, Aspergillus niger, and Candida albicans. Of the guanylsulfonamides, 13e and 13f displayed better antibacterial activities than that of Norfloxacin against the bacterial strains S. aureus and S. faecalis except 13f against S. faecalis, which exhibited the activity similar to that of Norfloxacin. Against the fungal strains A. flavus and A. niger, 13g and 13h showed similar activities to that of Griseoflavin-16 except 13h against A. niger, which displayed a profound drop in the activity compared to that of Griseoflavin-16. The remarkable inhibition of the growth of the bacterial and fungal strains makes these substances promising microbial agents.

Bisaryl-sulfonamides

Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ or PPARδ. In particular, the compounds of the invention modulate the function of PPARγ or PPARδ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.

NOVEL ADENOSINE A3 RECEPTOR AGONISTS

The invention realizes that a series of sulfonamido derivatives with a conserved uronamide group at the 5' position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido deritatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals.

Neuropeptide Y antagonists

The compound is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.